Inhaled Corticosteroids for Asthma Study
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Recruiting
Phase 4
Interventional Study
Asthma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 10 – 80
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 50 (estimated)
- Sponsor
- Gelb, Arthur F., M.D. · Individual
Who this trial is looking for
This trial is looking for people with asthma who are stable and being treated. Participants will use inhaled medications while the researchers study their breathing and lung function.
Are You a Good Fit for This Trial?
You may be able to join if
- I am a non-smoker with a smoking history of less than 10 pack years.
- I am between 10 and 80 years old.
- I have moderate to severe asthma.
- I am currently being treated for asthma.
- I have FEV1/FVC less than 70% after taking 180ug albuterol.
You may not be able to join if
- I am pregnant.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists. The investigators are interested in determining whether the large and/or small airways are t…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Current non-smoking (\<10 pack yr smoking history)
* Stable, treated asthmatics
* Age 10-80 yr
* post 180ug albuterol by MDI: FEV 1/FVC \< 70% and FEV 1 \<80% predicted
Exclusion Criteria:
* Pregnancy
Contacts